nach oben

Erschienen in:

Open Access 06.02.2024 | Global Health Services Research

Contemporary Analysis of Reexcision and Conversion to Mastectomy Rates and Associated Healthcare Costs for Women Undergoing Breast-Conserving Surgery

verfasst von: Youngran Kim, PhD, Cecilia Ganduglia-Cazaban, MD, DrPH, Nina Tamirisa, MD, Anthony Lucci, MD, Trudy Millard Krause, DrPH

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study was designed to provide a comprehensive and up-to-date understanding of population-level reoperation rates and incremental healthcare costs associated with reoperation for patients who underwent breast-conserving surgery (BCS).

Methods

This is a retrospective cohort study using Merative™ MarketScan^® commercial insurance data and Medicare 5% fee-for-service claims data. The study included females aged 18–64 years in the commercial cohort and females aged 18 years and older in the Medicare cohort, who underwent initial BCS for breast cancer in 2017–2019. Reoperation rates within a year of the initial BCS and overall 1-year healthcare costs stratified by reoperation status were measured.

Results

The commercial cohort included 17,129 women with a median age of 55 (interquartile range [IQR] 49–59) years, and the Medicare cohort included 6977 women with a median age of 73 (IQR 69–78) years. Overall reoperation rates were 21.1% (95% confidence interval [CI] 20.5–21.8%) for the commercial cohort and 14.9% (95% CI 14.1–15.7%) for the Medicare cohort. In both cohorts, reoperation rates decreased as age increased, and conversion to mastectomy was more prevalent among younger women in the commercial cohort. The mean healthcare costs during 1 year of follow-up from the initial BCS were $95,165 for the commercial cohort and $36,313 for the Medicare cohort. Reoperations were associated with 24% higher costs in both the commercial and Medicare cohorts, which translated into $21,607 and $8559 incremental costs, respectively.

Conclusions

The rates of reoperation after BCS have remained high and have contributed to increased healthcare costs. Continuing efforts to reduce reoperation need more attention.

Nur mit Berechtigung zugänglich

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.PubMedCrossRef

Katipamula R, Degnim AC, Hoskin T, et al. Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol. 2009;27(25):4082–8.PubMedPubMedCentralCrossRef

Kummerow KL, Du L, Penson DF, et al. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg. 2015;150(1):9–16.PubMedCrossRef

Wazer DE, DiPetrillo T, Schmidt-Ullrich R, et al. Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol. 1992;10(3):356–63.PubMedCrossRef

King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol. 2011;29(16):2158–64.PubMedCrossRef

Pataky RE, Baliski CR. Reoperation costs in attempted breast-conserving surgery: a decision analysis. Curr Oncol. 2016;23(5):314–21.PubMedPubMedCentralCrossRef

Metcalfe LN, Zysk AM, Yemul KS, et al. Beyond the margins-economic costs and complications associated with repeated breast-conserving surgeries. JAMA Surg. 2017;152(11):1084–6.PubMedPubMedCentralCrossRef

Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Ann Surg Oncol. 2014;21(3):704–16.PubMedCrossRef

Morrow M, Van Zee KJ, Solin LJ, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. Ann Surg Oncol. 2016;23(12):3801–10.PubMedPubMedCentralCrossRef

10.

Toss MS, Pinder SE, Green AR, et al. Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins? Histopathology. 2017;70:681–92.PubMedCrossRef

11.

Marinovich ML, Noguchi N, Morrow M, Houssami N. Changes in reoperation after publication of consensus guidelines on margins for breast-conserving surgery: a systematic review and meta-analysis. JAMA Surg. 2020;155(10):e203025.PubMedPubMedCentralCrossRef

12.

Morrow M, Abrahamse P, Hofer TP, et al. Trends in reoperation after initial lumpectomy for breast cancer: addressing overtreatment in surgical management. JAMA Oncol. 2017;3(10):1352–7.PubMedPubMedCentralCrossRef

13.

Tamirisa N, Lei X, Caudle AS, Giordano SH, Zhao H, Chavez-MacGregor M. Impact of SSO-ASTRO “No Ink on Tumor” Guidelines on reexcision rates among older breast cancer patients. Ann Surg Oncol. 2021;28(7):3703–13.PubMedCrossRef

14.

Schulman AM, Mirrielees JA, Leverson G, et al. Reexcision surgery for breast cancer: an analysis of the American Society of Breast Surgeons (ASBrS) MasterySM database following the SSO-ASTRO “No Ink on Tumor” guidelines. Ann Surg Oncol. 2017;24(1):52–8.PubMedCrossRef

15.

Chavez-MacGregor M, Lei X, Morrow M, Giordano SH. Abstract P2–12-03: impact of the SSO-ASTRO consensus guidelines on invasive margins on the re-excision rate among patients undergoing breast conserving surgery (BCS). Cancer Res. 2018;78(4):2–3.

16.

Kantor O, Pesce C, Kopkash K, et al. Impact of the Society of Surgical Oncology-American Society for Radiation Oncology margin guidelines on breast-conserving surgery and mastectomy trends.

17.

Isaacs AJ, Gemignani ML, Pusic A, Sedrakyan A. Association of breast conservation surgery for cancer with 90-day reoperation rates in New York State. JAMA Surg. 2016;151(7):648–55.PubMedCrossRef

18.

Valero MG, Mallory MA, Losk K, et al. Surgeon variability and factors predicting for reoperation following breast-conserving surgery. Ann Surg Oncol. 2018;25:2573–8.PubMedPubMedCentralCrossRef

19.

Kaczmarski K, Wang P, Gilmore R, et al. Surgeon re-excision rates after breast-conserving surgery: a measure of low-value care. J Am Coll Surg. 2019;228(4):504-12.e2.PubMedCrossRef

20.

Wang T, Bredbeck BC, Sinco B, Shubeck S, Baskin AS, Skolarus T, Dossett LA. Variations in persistent use of low-value breast cancer surgery. JAMA Surg. 2021;156(4):353–62.PubMedCrossRef

21.

Langhans L, Jensen M-B, Talman M-LM, Vejborg I, Kroman N, Tvedskov TF. Reoperation rates in ductal carcinoma in situ vs invasive breast cancer after wire-guided breast-conserving surgery. JAMA Surg. 2017;152(4):378–84.PubMedPubMedCentralCrossRef

22.

Ernster V, Ballard-Barbash R, Barlow W, et al. Detection of DCIS in women undergoing screening mammography. J Natl Cancer Inst. 2002;94(20):1546–54.PubMedCrossRef

23.

Luiten JD, Luiten EJT, van der Sangen MJC, et al. Patterns of treatment and outcome of ductal carcinoma in situ in the Netherlands. Breast Cancer Res Treat. 2021;187(1):245–54.PubMedPubMedCentralCrossRef

24.

Kerlikowske K. Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monographs. 2010;2010(41):139–41.CrossRef

25.

Petruolo O, Sevilimedu V, Montagna G, Le T, Morrow M, Barrio AV. How often does modern neoadjuvant chemotherapy downstage patients to breast-conserving surgery? Ann Surg Oncol. 2021;28(1):287–94.PubMedCrossRef

26.

Thawanyarat K, Johnstone T, Rowley M, Navarro Y, Hinson C, Nazerali RS. Optimizing postoperative outcomes following neoadjuvant chemotherapy and mastectomy with immediate reconstruction: a national analysis. J Surg Oncol. 2023;127(5):768–75.PubMedCrossRef

27.

Jonczyk MM, Jean J, Graham R, Chatterjee A. Surgical trends in breast cancer: a rise in novel operative treatment options over a 12 year analysis. Breast Cancer Res Treat. 2019;173(2):267–74.PubMedCrossRef

28.

Smith BD, Jiang J, Shih YC, et al. Cost and complications of local therapies for early-stage breast cancer. J Natl Cancer Inst. 2016;109(1):djw178. Erratum in: J Natl Cancer Inst. 2018;110(10):1148–52.

29.

Chakedis JM, Tang A, Savitz A, et al. Economic impact of reducing reexcision rates after breast-conserving surgery in a large, integrated health system. Ann Surg Oncol. 2022;29(10):6288–96.PubMedCrossRef

30.

Reinhardt UE. The pricing of U.S. hospital services: chaos behind a veil of secrecy. Health Aff. 2006;25(1):57–69.CrossRef

31.

Grant Y, Al-Khudairi R, St John E, et al. Patient-level costs in margin re-excision for breast-conserving surgery. Br J Surg. 2019;106(4):384–94.PubMedCrossRef

32.

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7.CrossRef

33.

Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–51.PubMedCrossRef

34.

Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.PubMedCrossRef

35.

Cancer Medications Enquiry Database (CanMED). Surveillance Research Program SEER website tool. Division of Cancer Control and Population Sciences, National Cancer Institute. Version 1.14.0, 2023. Accessed on 1 May 2023 from https://seer.cancer.gov/oncologytoolbox/canmed

36.

Cassel CK, Guest JA. Choosing wisely: helping physicians and patients make smart decisions about their care. JAMA. 2012;307(17):1801–2.PubMedCrossRef

37.

Antunez AG, Telem DA, Dossett LA. Assessment of surgical specialty societies’ Choosing Wisely recommendations. JAMA Surg. 2019;154(10):971–3.PubMedPubMedCentralCrossRef

38.

Schumacher JR, Lawson EH, Kong AL, et al. A statewide approach to reducing re-excision rates for women with breast-conserving surgery. Ann Surg. 2022;276(4):665–72.PubMedCrossRef

39.

Schmidt H, Connolly C, Jaffer S, et al. Evaluation of surgically excised breast tissue microstructure using wide-field optical coherence tomography. Breast J. 2020;26(5):917–23.PubMedCrossRef

40.

Hwang ES, Beitsch P, Blumencranz P, et al. Clinical impact of intraoperative margin assessment in breast-conserving surgery with a novel pegulicianine fluorescence-guided system: a nonrandomized controlled trial. JAMA Surg. 2022;157(7):573–80.PubMedPubMedCentralCrossRef

41.

Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25(33):5203–9.PubMedCrossRef

42.

Tuttle TM, Jarosek S, Habermann EB, Arrington A, Abraham A, Morris TJ, Virnig BA. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 2009;27(9):1362–7.PubMedCrossRef

43.

Heeg E, Jensen MB, Hölmich LR, et al. Rates of re-excision and conversion to mastectomy after breast-conserving surgery with or without oncoplastic surgery: a nationwide population-based study. Br J Surg. 2020;107(13):1762–72.PubMedCrossRef

44.

Tse T, Sehdev S, Seely J, et al. Neoadjuvant chemotherapy in breast cancer: review of the evidence and conditions that facilitated its use during the global pandemic. Curr Oncol. 2021;28(2):1338–47.PubMedPubMedCentralCrossRef

45.

Habbous S, Tai X, Beca JM, et al. Comparison of use of neoadjuvant systemic treatment for breast cancer and short-term outcomes before vs during the COVID-19 Era in Ontario, Canada. JAMA Netw Open. 2022;5(8):e2225118.PubMedPubMedCentralCrossRef

46.

Fu R, Sutradhar R, Dare A, et al. Cancer patients first treated with chemotherapy: are they more likely to receive surgery in the pandemic? Curr Oncol. 2022;29(10):7732–44.PubMedPubMedCentralCrossRef

47.

Boughey JC, Peintinger F, Meric-Bernstam F, et al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006;244(3):464–70.PubMedPubMedCentralCrossRef

Titel: Contemporary Analysis of Reexcision and Conversion to Mastectomy Rates and Associated Healthcare Costs for Women Undergoing Breast-Conserving Surgery
verfasst von: Youngran Kim, PhD
Cecilia Ganduglia-Cazaban, MD, DrPH
Nina Tamirisa, MD
Anthony Lucci, MD
Trudy Millard Krause, DrPH
Publikationsdatum: 06.02.2024
Verlag: Springer International Publishing
Erschienen in: Annals of Surgical Oncology / Ausgabe 6/2024
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-024-14902-z

Neu im Fachgebiet Chirurgie

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Contemporary Analysis of Reexcision and Conversion to Mastectomy Rates and Associated Healthcare Costs for Women Undergoing Breast-Conserving Surgery